MoneyWorks4Me

Bacil Pharma - Quaterly Results

23 Oct 2024 Evaluate
Revenue showed a marginal decline at Rs. 0.00 millions. For the quarter ended September 2024, as compared to corresponding quarter of last year.The Total Profit for the quarter ended September 2024 of Rs. 4.85 millions grew from Rs.-0.12 millions Operating profit Margin for the quarter ended September 2024 improved to 4.88% as compared to -0.11% of corresponding quarter ended September 2023


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202409 202309 % Var 202409 202309 % Var 202403 202303 % Var
Sales 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other Income 5.60 0.29 1831.03 5.71 0.77 641.56 1.31 1.15 13.91
PBIDT 4.88 -0.11 -4536.36 4.55 0.07 6400.00 -0.57 -0.99 -42.42
Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PBDT 4.88 -0.11 -4536.36 4.55 0.07 6400.00 -0.57 -0.99 -42.42
Depreciation 0.00 0.01 -100.00 0.00 0.02 -100.00 0.02 0.03 -33.33
PBT 4.88 -0.12 -4166.67 4.55 0.05 9000.00 -0.59 -1.02 -42.16
TAX 0.03 0.00 0.00 0.03 0.00 0.00 0.00 0.00 0.00
Deferred Tax 0.03 0.00 0.00 0.03 0.00 0.00 0.00 0.00 0.00
PAT 4.85 -0.12 -4141.67 4.52 0.05 8940.00 -0.59 -1.02 -42.16
Equity 58.90 58.90 0.00 58.90 58.90 0.00 58.90 58.90 0.00
PBIDTM(%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Peers
Company Name CMP
Sun Pharma. Inds. 1820.00
Dr. Reddys Labs. 1236.00
Cipla 1350.00
Lupin 2042.00
Zydus Lifesciences 1163.35
View more..